Pembrolizumab Associated With Long-Term Survival in Advanced Melanoma
A new study has shown that 40% of patients with previously treated advanced melanoma were alive at three years’ follow-up after initiating treatment with pembrolizumab. The results were presented at the 2016 American Society of Clinical Oncology annual meeting.
August 09, 2016
What Nurses Need to Know About Talimogene Laherparepvec for Advanced Melanoma
A number of different oncolytic immunotherapies are in development for advanced melanoma, one of which is talimogene laherparepvec, a genetically modified recombinant herpes simplex virus type 1.
July 12, 2016
FDA Approves Combination of Mekinist and Tafinlar for Advanced Melanoma
The U.S. Food and Drug Administration (FDA) granted accelerated approval to trametinib (Mekinist tablets, GlaxoSmithKline, LLC) and dabrafenib (Tafinlar capsules, GlaxoSmithKline, LLC) for use in combination in the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation as detected by an FDA-approved test.
January 10, 2014
FDA Approves Dabrafenib for Unresectable or Metastatic Melanoma
On May 29, 2013, the U.S. Food and Drug Administration (FDA) approved dabrafenib (Tafinlar™ capsule, GlaxoSmithKline), for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
May 30, 2013